TrialActa ophthalmologica2021

Systemic counterregulatory response of angiopoietin-2 after aflibercept therapy for nAMD: a potential escape mechanism.

Reinhard Angermann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.